John B. Haanen

Aug 14, 2024 | jamanetwork.com | Amsterdam UMC |Manja Bloem |John B. Haanen |Hilde Jalving

Key PointsQuestion  What are the long-term outcomes of patients with advanced melanoma who are treated in daily clinical practice, and do they have a chance of sustaining long-term survival? Findings  In this cohort study including 2490 patients with advanced melanoma treated with first-line immune checkpoint inhibitors, survival curves flattened over time, suggesting long-term survival.

Jul 26, 2024 | mdpi.com | Olivier van Not |Remco van Doorn |John B. Haanen |Melissa de Meza

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Feb 11, 2024 | thelancet.com | John B. Haanen |Christian Blank |Maureen J.B. Aarts |Ellen Kapiteijn

SummaryThe prognosis of advanced melanoma patients has significantly improved over the years. We aimed to evaluate the survival per year of diagnosis. All systemically treated patients diagnosed with advanced melanoma from 2013 to 2021 were included from the Dutch Melanoma Treatment Registry. Baseline characteristics and overall survival (OS) were compared between the different years of diagnosis.

Jan 11, 2024 | acsjournals.onlinelibrary.wiley.com | John B. Haanen |Christian Blank |Marye J. Boers-Sonderen |Ellen Kapiteijn

INTRODUCTION The BRAF gene is a proto-oncogene encoding B-Raf kinase, which is important for cell signaling and growth.

Jan 1, 2024 | jitc.bmj.com | John B. Haanen |Marjolein Metselaar-Albers |Irma Meijerman |Ferdi Engels

Discussion and conclusionOur study suggests that antibiotic therapy at cancer treatment initiation does not detrimentally impact ICI therapy response in melanoma and NSCLC. The magnitude of decreased OS in antibiotic users was similar between individuals on ICI therapy (HR=1.28; 95% CI 1.07 to 1.52) and those on TKIs (HR=1.20; 95% CI 0.92 to 1.57; synergy index=0.96; 95% CI 0.71 to 1.31).